Wallace Rheumatic Studies Center — research payments reported

By program year

4 rows

Year	Kind	Amount	Payments
2024	Research	$392	2
2023	Research	$74	2
2022	Research	$48,060	13
2019	Research	$950	2

Breakdown

Who paid Research payments · program years 2019–2024

AbbVie, Inc. $48,060 13 payments
Amgen Inc. $880 1 payment
Ucb SA $451 3 payments
Pfizer Inc. $70 1 payment
E.R. Squibb & Sons, L.L.C. $15 1 payment

Studies the money was for Research payments · program years 2019–2024

A Study to Investigate the Safety and Efficacy of Elsubrutinib and Upadacitinib Given Alone or in Combination in Participants With Moderately to Severely Active Systemic Lupus Erythematosus (SLE) $48,060 13 payments
Ph 1b/2b in Subjects withSLE $880 1 payment
A Multicenter, Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of Dapirolizumab Pegol Treatment in Study Participants With Systemic Lupus Erythematosus $373 1 payment
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus $77 2 payments
A Ph2 Doubleblind Randomized Placebocontrolled Multicenter Doseranging Study to Evaluate the Efficacy and Safety Profile of Pf06700841 in Subjects With Systemic Lupus Erythematosus $70 1 payment
MAD in Patients/Phase 1B (Lupus) - A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986326 in Adult Participants with Discoid Lupus $15 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.